Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

11 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling of human breast cancer samples that were treated with tamoxifen identifier a 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy

ABSTRACT: Classification of tamixifen-treated breast cancer patients into high and low risk groups using the 76-gene signature Experiment Overall Design: 136 breast cancer samples that were treated with tamoxifen were classified using the 76-gene signature

ORGANISM(S): Homo sapiens

SUBMITTER: Jack Yu

PROVIDER: E-GEOD-12093 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.

Zhang Yi Y Sieuwerts Anieta M AM McGreevy Michelle M Casey Graham G Cufer Tanja T Paradiso Angelo A Harbeck Nadia N Span Paul N PN Hicks David G DG Crowe Joseph J Tubbs Raymond R RR Budd G Thomas GT Lyons Joanne J Sweep Fred C G J FC Schmitt Manfred M Schittulli Francesco F Golouh Rastko R Talantov Dmitri D Wang Yixin Y Foekens John A JA

Breast cancer research and treatment 20080923 2

<h4>Purpose</h4>To assess the benefit from adjuvant systemic tamoxifen therapy in breast cancer risk groups identified by the previously established prognostic 76-gene signature.<h4>Methods</h4>In 300 lymph node-negative (LNN), estrogen receptor-positive (ER+) breast cancer patients (136 treated with adjuvant tamoxifen, 164 having received no systemic adjuvant therapy), distant metastasis-free survival (DMFS) as a function of the 76-gene signature was determined in a multicenter fashion.<h4>Resu ...[more]

PMID: 18821012

Similar Datasets

The 76-gene Signature Defines High-Risk Patients that Benefit from Adjuvant Tamoxifen Therapy

Project description:Classification of tamixifen-treated breast cancer patients into high and low risk groups using the 76-gene signature

2008-10-07 | GSE12093 | GEO

Transcription profiling of human breast cancer samples that were treated with tamoxifen identifier a 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy

Project description: Not available

| S-ECPF-GEOD-12093 | biostudies-other

Transcription profiling of human primary breast tumors to validate a 76-gene prognostic signature reveals strong time dependence of the 76-gene prognostic signature

Project description:Background: Recently a 76-gene prognostic signature able to predict distant metastases in lymph node-negative (N-) breast cancer patients was reported. The aims of this study conducted by TRANSBIG were to independently validate these results and to compare the outcome with clinical risk assessment. Materials and Methods: Gene expression profiling of frozen samples from 198 N- systemically untreated patients was performed at the Bordet Institute, blinded to clinical data and independent of Veridex. Genomic risk was defined by Veridex, blinded to clinical data. Survival analyses, done by an independent statistician, were performed with the genomic risk and adjusted for the clinical risk, defined by Adjuvant!Online. Results: The actual 5- and 10-year time to distant metastasis (TDM) were 98% (88%-100%) and 94% (83%-98%) respectively for the good profile group and 76% (68%- 82%) and 73% (65%-79%) for the poor profile group. The actual 5- and 10-year overall survival (OS) were 98% (88%-100%) and 87% (73%-94%) respectively for the good profile group and 84% (77%-89%) and 72% (63%-78%) for the poor profile group. We observed a strong time-dependency of this signature, leading to an adjusted HR of 13.58 (1.85-99.63) and 8.20 (1.10-60.90) at 5 years, and 5.11 (1.57-16.67) and 2.55 (1.07-6.10) at 10 years for TDM and OS respectively. Conclusion: This independent validation confirmed the performance of the 76-gene signature and adds to the growing evidence that gene expression signatures are of clinical relevance, especially for identifying patients at high risk of early distant metastases. Experiment Overall Design: dataset of microarray experiments from primary breast tumors used to validate the 76-gene signature (VERIDEX). No replicate, no reference sample.

2008-06-16 | E-GEOD-7390 | biostudies-arrayexpress

Acidovorax sp. 76 strain:76

Project description:Acidovorax sp. 76 strain:76 Genome sequencing

| PRJNA442010 | ENA

Streptomyces sp. 76 strain:76

Project description:Streptomyces sp. 76 strain:76 Genome sequencing

| PRJNA402581 | ENA

Strong Time Dependence of the 76-Gene Prognostic Signature

2007-06-11 | GSE7390 | GEO

proteotypes of 76 breast cancer cell lines by PCT-SWATH

Project description:Here we obtained the proteotypes of 76 breast cancer cell lines using pressure cycling technology (PCT) and SWATH mass spectrometry.

2021-01-13 | PXD004701 | Pride

SNP data from 76 adrenocortical carcinomas

Project description:SNP array data from 76 adrenocortical carcinomas were used to detect recurrent copy number alterations.

2014-04-07 | GSE52296 | GEO

CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.

Project description: Not available

| S-EPMC3695326 | biostudies-literature

Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant Tamoxifen mono-therapy: a DBCG study

Project description:Purpose: Despite the benefits of estrogen receptor (ER)-targeted endocrine therapies in breast cancer, many tumors develop resistance. MicroRNAs (miRNAs) have been suggested as promising biomarkers and we here evaluated whether a miRNA profile could be identified, sub-grouping ER+ breast cancer patients treated with adjuvant Tamoxifen with regards to probability of recurrence. Experimental design: Global miRNA analysis was performed on 152 ER+ primary tumors from high-risk breast cancer patients with an initial discovery set of 52 patients, followed by 2 independent test sets (N=60 and N=40). All patients had received adjuvant Tamoxifen as mono-therapy (median clinical follow-up: 4.6 years) and half had developed distant recurrence (median time-to-recurrence: 3.5 years). MiRNA expression was examined by unsupervised hierarchical clustering and supervised analysis, including clinical parameters as co-variables.

2012-04-19 | GSE37405 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data